# Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

> **NCT04803123** · EARLY_PHASE1 · TERMINATED · sponsor: **Dorothy Sipkins, MD, PhD** · enrollment: 3 (actual)

## Conditions studied

- Leukemia, Acute Lymphocytic

## Interventions

- **DRUG:** Copanlisib

## Key facts

- **NCT ID:** NCT04803123
- **Lead sponsor:** Dorothy Sipkins, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-21
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-04-26
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor halted clinical development of study drug
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803123, "Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04803123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*